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a b s t r a c t
Yellow fever (YF) causes an acute hemorrhagic fever disease in tropical Africa and Latin America. To
develop a novel experimental YF vaccine, we applied iDNA infectious clone technology. The iDNA
represents plasmid that encodes the full-length RNA genome of 17D vaccine downstream from
a cytomegalovirus (CMV) promoter. The vaccine was designed to transcribe the full-length viral RNA
and to launch 17D vaccine virus in vitro and in vivo. Transfection with 10 ng of iDNA plasmid was
sufﬁcient to start replication of vaccine virus in vitro. Safety of the parental 17D and iDNA-derived 17D
viruses was conﬁrmed in AG129 mice deﬁcient in receptors for IFN-α/β/γ. Finally, direct vaccination of
BALB/c mice with a single 20 μg dose of iDNA plasmid resulted in seroconversion and elicitation of virus-
speciﬁc neutralizing antibodies in animals. We conclude that iDNA immunization approach combines
characteristics of DNA and attenuated vaccines and represents a promising vaccination strategy for YF.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Yellow fever (YF) virus (YFV) is a major public health problem
in Africa and South America, with a history of causing epidemics
worldwide including the U.S. (Ishikawa et al., 2014; Paessler and
Walker, 2013; Weaver, 2013). The World Health Organization
estimates 200,000 cases of YF and 30,000 deaths worldwide
annually. Geographic distribution of YF endemicity currently
covers mostly tropical areas of Africa and South America (Beck
et al., 2013; Jentes et al., 2011). Phylogenetic and epidemiological
analysis supports a model of YFV emergence that is dependent
upon both the presence of competent mosquito vectors and
nonhuman primate reservoir hosts (Grard et al., 2010; Quaresma
et al., 2013). The dynamic ecological and climatic changes asso-
ciated with international travel, trade, and urbanization increase
the potential of YF spread to previously non-endemic regions of
the world (Weaver, 2013).
The enveloped, 50 nm YFV particle contains a single-stranded,
positive-sense RNA genome of approximately 10.8 kb, including a
50 cap, as well as 50 and 30 terminal untranslated regions, without
30 polyA tail (Heinz and Stiasny, 2012; Ishikawa et al., 2014;
Paessler and Walker, 2013). Following isolation of YF virus in
1927, the YF 17D vaccine was developed in 1937 by 176 passages of
Asibi strain in chicken embryo tissue to remove its neurotropic
characteristics (Ishikawa et al., 2014; Staples and Monath, 2008).
Currently, substrains 17D-204, 17D-213, and 17DD are used for
vaccine manufacturing. Although genetically distinct, all three
substrains are immunogenic and efﬁcacious, with amino acid
substitutions likely responsible for attenuation (dos Santos et al.,
1995; Jennings et al., 1993; Lang et al., 1999). A single dose of
vaccine confers life-long protective immunity; therefore, a booster
dose is not needed in most cases (Gotuzzo et al., 2013; Patel and
Simons, 2013).
The available safety data support continued the use of YF 17D
vaccine for preventive vaccination campaigns in endemic areas
(Breugelmans et al., 2013; Cottin et al., 2013; Garske et al., 2014).
The vaccine has also been used as a backbone to develop other
ﬂavivirus vaccines (Bredenbeek et al., 2006; Guy et al., 2011,
2010; Ishikawa et al., 2014; Stoyanov et al., 2010). Active case-
analyses in several countries found only rare 17D vaccine-
associated adverse effects including YF vaccine-associated neu-
rologic disease (YEL-AND) and viscerotropic disease (YEL-AVD),
as well as allergic reactions (Breugelmans et al., 2013; Ishikawa
et al., 2014; Rafferty et al., 2013). Some adverse events appear to
be associated with host factors rather than with the vaccine
(Barban et al., 2007). Because the vaccine is still manufactured
using chicken embryos, egg allergy is a contraindication for
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vaccination (Rutkowski et al., 2013). Thus, alternative strategies
are still needed to improve YF vaccination. Attempts to prepare
new vaccines were hampered due to genetic instability of the YF
cDNA clones in E. coli (Bredenbeek et al., 2003; Rice et al., 1989).
In order to develop a novel experimental vaccine and a reverse
genetics system for YF, we applied recently described “immuni-
zation DNA” (iDNAs) platform, which is based on a molecular
clone technology and combines advantages of DNA immunization
and efﬁcacy of live attenuated vaccines (Tretyakova et al., 2014,
2013). We showed that iDNA can successfully launch the YF 17D
vaccine virus in vitro. Moreover, injection of iDNA plasmid into
BALB/c mice resulted in virus-speciﬁc immune responses in vivo,
suggesting the potential use of iDNA technology as novel YF
vaccine.
Materials and methods
Cell lines and viruses
African green monkey Vero cell line was obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and
maintained in a humidiﬁed incubator at 37 1C and 5% CO2 in
αMEM medium supplemented with 10% fetal bovine serum (FBS)
and gentamicin sulfate (10 μg/ml) (Life Technologies, Carlsbad,
CA). The YF live attenuated vaccine strain 17D (NR-116) was
obtained from the NIH Biodefense and Emerging Infections
Research Resources Repository, NIAID, NIH. The sequence
X03700 is available from Genbank. The 17D vaccine virus was
propagated in Vero cells in 75 cm2 ﬂask to generate passage 1 (P1)
virus. At 9 days post-infection, the 17D P1 virus was harvested,
clariﬁed by centrifugation at 3000 g for 10 min, and frozen
at 80 1C.
Plasmids and preparation of iDNA
Plasmid pACNR- FLYF\17D encoding the full-length YF 17D
cDNA downstream from the bacteriophage SP6 promoter was a
kind gift from Dr. Peter Bredenbeek (LUMC, Leiden, Netherlands)
and was described elsewhere (Bredenbeek et al., 2003). The CMV
major immediate-early promoter was inserted into the pACNR-
FLYF\17D plasmid upstream from the full-length 17D cDNA. This
resulted in the pYF17D-5 iDNA plasmid that encoded the 17D full-
length genomic RNA under transcriptional control of the CMV
promoter (Fig. 1). Additional iDNA plasmid pYF17D-16 was pre-
pared by inserting synthetic intron between 17D nucleotides (nt)
9152 and 9153 within the pYF17D-5 plasmid. Intron sequence was
derived from mouse immunoglobulin H chain V-region precursor
gene (Genbank accession M12880) and inserted into 17D cDNA to
inactivate cryptic E. coli promoters and eliminate a potentially
toxic polypeptide that may reduce genetic stability of the YF cDNA.
The E. coli promoters have been predicted by using BPROM
software (SoftBerry, Mount Kisco, NY). The resulting iDNAs were
isolated from E.coli strains DH5α or Stbl3 as indicated.
Transfections and assays in vitro
Vero cells were transfected by electroporation with indicated
plasmid iDNA at concentrations ranging from 10 ng to 1 μg.
Transfection was carried out essentially as described previously
(Messer et al., 2012; Tretyakova et al., 2013). As 17D virus controls,
Vero cells were infected with 103 PFU of 17D vaccine virus.
Production of virus and expression of 17D antigens in the iDNA-
transfected cells were determined by the infectious center assay
(ICA), indirect immunoﬂuorescence assay (IFA) and western blot.
For ICA, iDNA-transfected Vero cells were diluted 10-fold in
complete αMEM containing 10% FBS, allowed to adhere for 4 h in
C 3
pYF17D-5 
C 3
pYF17D-16  
Intron  
1 10862 CMV 
CMV 
Full-Length YF 17D cDNA  
5
5
9152 nt  
Infectious center assay, ICA 
pYF17D-5                    pYF17D-16 
DH5        Stbl3       DH5           Stbl3 
pYF17D-5                 pYF17D-16 
12kB- 
Immunofluorescence assay, IFA 
pYF17D-5                          pYF17D-16 
Fig. 1. Preparation of YF 17D iDNA plasmids encoding the full-length 17D RNA downstream from the CMV promoter. (a) Schematic depiction of two iDNA plasmids, pYF17D-
5 and pYF17D-16. Indicated are CMV promoter (shaded arrow), positions of the 50 and 30 ends of the full-length 17D cDNA, as well as intron within pYF17D-16 (shaded box).
The 17D nucleotides are indicated according to 17D genome, Genbank X03700 (b) Plasmid yields in E. coli DH5α and Stbl3 cells. Miniprep DNA isolations were performed
from each E. coli strain as indicated. The DNA yields were compared by gel densitometry analysis. (c) Infectious center assay (ICA) of Vero cells transfected with 200 ng of
pYF17D-5 and pYF17D-16 iDNA. Transfected cells were covered with 1% agarose overlay and incubated for 4 days to form plaques, which were visualized using neutral red.
(d) Indirect immunoﬂuorescence assay (IFA) of Vero cells transfected with 200 ng of pYF17D-5 and pYF17D-16 iDNA. After transfection, aliquots of transfected Vero cells
were seeded in 8-well chamber slides, ﬁxed at 72 h in cold acetone and processed by IFA using YF-speciﬁc mouse polyclonal antiserum and FITCI-conjugated goat antibody to
mouse IgG (HþL). Propidium iodide (PI) counterstain was used to visualize cell nuclei. Expression of 17D antigens after transfection of iDNA plasmid is indicated by green
ﬂuorescent Vero cells.
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6-well plates, and covered with 1% agarose overlay. Plates were
incubated at 371C in 5% CO2 for 4 days to form plaques, which
were visualized using neutral red. For IFA, iDNA-transfected or
17D-infected Vero cells were seeded in 8-well chamber slides in
complete αMEM. At 48 h posttransfection, cells were ﬁxed with
cold acetone, and IFA was done using YF-speciﬁc mouse antiserum
followed by secondary ﬂuorescein-labeled antibody to mouse IgG
(HþL). For western blot, Vero cells transfected with iDNA or
infected with 17D virus were harvested on day 9, solubilized in
the protein sample buffer, and proteins were separated by 4–12%
SDS-PAGE. Finally, the virus presence in the growth medium was
conﬁrmed by plaque assay. For virus growth curves, samples were
taken at indicated time intervals. Average and standard deviation
values were determined. Each experiment was conducted at least
two times to ensure reproducibility.
Infection of AG129 mice with YF 17D and pYF17D-16 viruses
The AG129KO mice (129/Sv/Ev background), female, 4–5
weeks old, deﬁcient in IFN-α/β/γ receptors were purchased
from B&K Universal Ltd. (Grimston, Aldbrough Hill, UK). Mice
were randomly placed into two groups (n¼30) and inoculated
with a single 100 ml intraperitoneal (i.p.) injection (105 PFU/
mouse) of either parental YF 17D vaccine or with iDNA-derived
pYF17D-16 virus. Between days 0 and 12 post-inoculation (p.i.)
3 mice from each group were sacriﬁced every 3 days. Beginning
at day 12 p.i., mice were euthanized upon exhibiting signs of
morbidity. Tissue samples were collected and stored in liquid
nitrogen before RNA puriﬁcation. Quantitative RT/PCR with the
8280F primer, CCACTCATGAAATGTACTACGTGTCTG; 8354r pri-
mer, GGAGGCGGGATGTTTGGT, and ﬂuorogenic 8308pr probe,
AGCCCGCAGCAATGTCACATTTACTGT, was performed as pre-
viously described (Thibodeaux et al., 2012) and viral genome
copies were calculated and expressed as viral genome equiva-
lents per 100 mg of tissues. At day 0, 6, and 15 two additional
mice from each group were euthanized, samples of liver, brain,
kidney, and spleen were removed, ﬁxed in 10% formalin, then
samples were prepared for parafﬁn-embedding, sectioning and
hematoxylin and eosin (H&E) staining.
Immunizations and serology
The iDNA plasmid was isolated from E.coli and formulated in
phosphate-buffered saline (PBS) to a ﬁnal concentration of 0.4 mg/ml.
Four-week-old female BALB/c mice were anesthetized with isoﬂurane
and vaccinated intramuscularly (i.m.) with a dose of 50 μl of pYF17D-
16 iDNA vaccine in the medial thighs (Noble Life Sciences, Gaithers-
burg, MD). After injection of iDNA, animals were electroporated as
described elsewhere (Tretyakova et al., 2013). As a control, the YF 17D
virus (104 PFU) was injected subcutaneously (s.c.). After vaccinations,
animals were observed daily for clinical signs of infection. Sera were
collected on days 2 and 4 for viremia test, and at day 21 for antibody
response determination. For viremia detection, sera were pooled and
incubated with Vero cells for 3 days followed by observation for
cytopathic effects (CPE) and plaque assay. To determine antibody
responses, plaque reduction neutralization test (PRNT), western blot,
and IFA were performed. For PRNT, an equal volume (0.1 ml) of virus
suspension containing 500 PFU/ml and serial two-fold dilutions of
heat-inactivated serum were incubated 1 h at 37 1C, and the serum-
virus mixture was plated onto Vero cell monolayers in 12-well plates.
An agarose overlay of in αMEM was added and plates were incubated
at 37 1C for 3 days prior to neutral red staining and plaque count
determination. The endpoint PRNT50 or PRNT80 were expressed as the
highest dilution of serum that reduces plaques by 50% or 80%,
respectively, as compared to control serum collected before vaccina-
tion. For IFA, Vero cells were initially infected with 102 PFU/well of 17D
virus in chamber slides for 24 h in complete αMEM. Then, infected
Vero cells were ﬁxed with acetone and used as immobilized antigen to
detect YF-speciﬁc antibodies in the sera from experimental mice.
Results
Design and preparation of YF 17D iDNA
The YF 17D iDNA plasmids were prepared by inserting CMV
major immediate-early promoter upstream from the full-length YF
17D cDNA. For this purpose we used plasmid pACNR- FLYF\17D
that contained the full-length cDNA of YF 17D virus downstream
from the SP6 RNA polymerase promoter (Bredenbeek et al., 2003).
The SP6 promoter within the pACNR- FLYF\17D plasmid was
replaced with the CMV promoter to generate the YF 17D iDNA
plasmid pYF17D-5 containing the full-length cDNA of YF strain
17D genomic RNA downstream from the CMV promoter (Fig. 1a).
Because the authentic 50 terminus of RNA is important for
ﬂavivirus replication (Khromykh et al., 2001), the distance
between the CMV promoter and the 50 of 17D RNA was optimized
to ensure transcription of the functional YF 50 terminus of the 17D
genomic RNA. The resulting pYF17D-5 was conﬁrmed by sequen-
cing and contained the full-length YF 17D cDNA. Consistent with
previous observations (Bredenbeek et al., 2003; Rice et al., 1989),
pYF17D-5 showed low plasmid production yields in E. coli strain
DH5α as well as in strain Stbl3 (Fig. 1b). It has been hypothesized
that YF cDNA contains cryptic bacterial promoters that drive
synthesis of toxic proteins thus affecting genetic stability and
DNA yields in E. coli (Bredenbeek et al., 2003). In an attempt to
improve genetic stability and increase plasmid production, we
prepared iDNA plasmid pYF17D-16 (Fig. 1a), which was essentially
identical to the pYF17D-5, except it contained an 82 nt-long intron
inserted at nucleotide 9152 of the full-length YF 17D cDNA. The
site for intron insertion was chosen by predicting bacterial
promoters within 17D sequence using BPROM software. Putative
bacterial promoters have been identiﬁed at nt 8617 and 9012. The
intron was inserted at nt 9152 and contained ﬁve stop codons to
prevent translation of downstream putative polypeptides in E. coli.
The plasmids pYF17D-16 and pYF17D-5 were isolated from E. coli
DH5α or Stbl3 cells. The yield pYF17D-16 was equivalent or higher
than that of the pYF17D-5. For example, in one experiment, the
yield of pYF17D-16 from DH5α cells was approximately 2 times
higher than that of pYF17D-5, as determined by gel densitometry
(Fig. 1b).
Launch of YF vaccine virus replication from iDNA in vitro
The YF 17D pYF17D-5 and pYF17D-16 iDNA plasmids were
isolated from E.coli Stbl3, resulting in a sterile, endotoxin-free DNA
with 95% supercoiled fraction and an A260/A280 ratio of 1.9. In
order to launch replication of live 17D vaccine virus in vitro, iDNA
plasmids were transfected into Vero cells by electroporation. The
transfected Vero cells were analyzed for expression of 17D anti-
gens by ICA, IFA and western blot. For ICA, a suspension of
electroporated Vero cells was seeded into 6-well plates and over-
laid with 1% agarose. At 96 h, plaques were detected, indicating
replication of virus from the infectious centers, IC (Fig. 1c). Speciﬁc
infectivity of pYF17D-5 and pYF17D-16 was calculated at
1.0103 IC/μg and 1.3103 IC/μg, respectively. Expression of
YF 17D antigens in transfected cells was conﬁrmed at 72 h
posttransfection by IFA using mouse anti-YF polyclonal antiserum
(Fig. 1d). As expected for a ﬂavivirus, expression of 17D antigen
was found in the cytoplasm of transfected cells.
Expression of 17D antigens in iDNA-transfected cells was
further examined by SDS-PAGE and western blot. As a control,
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mock-electroporated Vero cells were infected with 103 PFU of 17D
virus. The antigen bands detected in iDNA-transfected Vero cells
were similar to those in the cells infected with 17D virus control
(Fig. 2a, lanes 1–3). SDS-PAGE and western blot conﬁrmed the
presence of 17D antigens that were consistent with molecular
weight of E, NS1, and prM proteins. As expected, no bands were
detected in the Vero uninfected control cells (Fig. 2a, lane 4). The
growth medium from iDNA-transfected Vero cells was examined
for the presence of replicating virus by plaque assay (Fig. 2b).
Plaques were detected in the supernatant samples of Vero cells
transfected with 200 ng of iDNA plasmids or infected with 103 PFU
of 17D virus suggesting that both pYF17D-5 and pYF17D-16 iDNA
plasmids have launched replication of live vaccine viruses and that
insertion of 82 nt-long intron did not affect the ability of pYF17D-
16 to initiate replication of live virus. Plaques from iDNA-
transfected cells appeared to be more uniform in size as compared
to the 17D virus. Growth curves of viruses from the transfected/
infected cells are shown in Fig. 2c. In the culture media from iDNA-
transfected cells, the titers reached 106 PFU/ml on day 5 post-
transfection, similar to the control 17D-infected cells. We observed
approximately 24 h delay for 17D control virus, which can be
explained by low amount (103 PFU) of virus used for infection.
In the next experiment, we determined the minimal dose of
iDNA sufﬁcient to launch live 17D virus in vitro. Vero cells were
transfected with pYF17D-16 iDNA plasmid with escalating doses
ranging from 10 ng to 1 μg. As a control, Vero cells were mock-
electroporated using PBS. As expected, no replicating virus was
detected in the mock-electroporated Vero cells. Transfection
of only 10 ng of iDNA resulted in the replication of 17D virus,
with virus titers reaching approximately 106 PFU/ml, similar to
transfections with higher quantities of DNA (Fig. 3). Since 17D is a
replicating virus, dependence of virus titer on the iDNA dose was
minimal. However, iDNA dose dependence was detectable as a
delayed onset of replication when 10 ng or 100 ng of iDNA is used.
These results suggest that the minimal dose of iDNA to launch 17D
virus in Vero cells is below 10 ng (Fig. 3), which corroborates our
previous ﬁndings with iDNA plasmids encoding VEEV or CHIKV
alphaviruses (Tretyakova et al., 2014, 2013).
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Replication of iDNA-derived YF17D in tissues of AG129 mice
To conﬁrm safety of the iDNA-derived virus, we used AG129
mice. It was previously determined that virulence of wild-type
YFV in mice is IFN-α/β-dependent (Lee and Lobigs, 2008; Meier
et al., 2009). Based on this observation, s.c. infection of IFN-α/β
deﬁcient mice is currently considered to be a biologically relevant
model of wild-type YFV infection (Meier et al., 2009). Mice
deﬁcient for receptors for both types of IFN, α/β and γ (AG129)
are also susceptible to YF 17D in a dose-dependent manner
(Thibodeaux et al., 2012). YF 17D virus does not persist in AG129
mice. Peripheral challenge with YF 17D results in 100% lethality at
dose-dependent manner ranging between 104 and 106 PFU. The YF
17D infection of AG129 mice results in high viral load in brain and
liver tissues providing a suitable model of human YF in BSL2
containment. We have used this model to compare replication
kinetics in brain tissues (neurotropism) and in liver (viscerotrop-
ism) of the parental YF 17D virus and the 17D virus derived from
pYF17D-16 iDNA-transfected Vero cells. Two groups of AG129 mice
were inoculated with viruses (105 PFU/mouse) and 3 mice from
each group were sacriﬁced every 3 days to collect tissues to extract
RNA and measure viral load.
As seen in Fig. 4a, both viruses replicated similarly in brain
tissues of infected mice. The viral RNA gradually accumulated
starting with day 3 and peaked on days 12–15 after infection. In
agreement with the previous study (Thibodeaux et al., 2012),
infected animals at this time point showed clinical signs of
neurotropic disease (paresis, high limb paralysis) and met eutha-
nasia criteria shorty after this time point. Replication kinetics of YF
17D and pYF17D-16 iDNA-derived virus in the liver tissues differed
from those in the brain. Both viruses replicated very rapidly at an
early stage of the infection. At day 3, 17D was detected in liver and
replicated efﬁciently peaking at day 6 with viral burden compar-
able with those in the brain on day 12–15. While replication
kinetic of both viruses was similar, replication of YF17D-16 virus in
liver was less active in comparison with the parental YF 17D
(Fig. 4b).
Early events after YF17D vaccination are critical for induction of
robust adaptive immune responses and correlate with early
production of IFN-γ (Neves et al., 2009, 2013). We measured IFN-
γ mRNA expression in the spleen and liver tissues of AG129 mice
infected with parental 17D and the 17D virus derived from
pYF17D-16 iDNA. Both vaccine viruses rapidly induced strong
expression of IFN-γ RNA in spleen, with no signiﬁcant differences
either in the scale or timing of induction (Fig. 4c). As expected,
IFN-γ mRNA induction was moderate in liver tissues (less cells are
susceptible for induction); however, the response in mice vacci-
nated with YF17D-16 virus peaked 72 h earlier in comparison
with animals injected with parental 17D. The magnitude of IFN-γ
mRNA induction in both groups of mice was similar (Fig. 4d).
Histological ﬁndings for both groups of infected mice by H&E-
stained sections prepared on day 6 and 15 after infection did not
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Fig. 4. Replication of YF 17D viruses in AG129 mice. AG129KO mice (129/Sv/Ev background) were inoculated with parental biological YF 17D virus or with YF 17D virus
recovered from YF17D-16 iDNA. Neurotropic, viscerotropic properties and induction of IFN-γ were assessed. Brieﬂy, three mice from each group were sacriﬁced at indicated
time points and neurotropic and viscerotropic features as well as induction of IFN-γ were measured as described in Materials and methods section. Panels (a) and (b),
replication kinetics and viral loads in brain and liver tissue, respectively. Panels (c) and (d), induction of IFN-γ mRNA in brain and liver tissue, respectively.
I. Tretyakova et al. / Virology 468-470 (2014) 28–3532
reveal distinct differences, with only a few foci with mild mono-
nuclear inﬂammation were observed in liver sections (data not
shown).
Immunogenicity of YF 17D-16 iDNA vaccine in BALB/c mice
To determine if pYF17D-16 iDNA plasmid is immunogenic
in vivo, BALB/c mice were vaccinated by injection-electroporation
with a single dose of pYF17D-16 iDNA. As a control, mice were
vaccinated by injection with YF parental 17D live virus vaccine.
Brieﬂy, mice were vaccinated with either a single i.m. injection of
20 μg of iDNA followed by electroporation, or injected s.c. with 104
PFU of YF 17D vaccine virus. After immunizations, all mice
remained healthy with no detectable pathology at the site of
injection or adverse effects due to vaccinations. No viremia was
detected on days 2 and 4 in both iDNA- and virus-vaccinated
groups either by direct plaque assay, or after incubating pooled
sera with Vero cells for 10 days followed by CPE analysis and
plaque assays. This result indicates no signiﬁcant presence of
replicating virus on days 2 and 4 after iDNA injection. In order to
detect antibodies by IFA, Vero cells were infected with 100 PFU
of 17D virus in chamber slides, ﬁxed, and then probed with
immunized mouse sera at 1:10 dilution (Fig. 5). On day 21, all
experimental iDNA-vaccinated mice, as well as 6 out of 7 virus-
control animals have seroconverted, as shown by IFA (Fig. 5).
Seroconvertion was conﬁrmed by PRNT (Table 1). Neutralizing
antibodies were detected in the serum of iDNA vaccinated animals
and were equivalent with, or exceeded, the neutralizing antibody
titers in the virus-vaccinated control animals (Table 1).
Discussion
Pathogenesis of YF is not fully understood, and there is no
approved speciﬁc antiviral therapy for YF (Julander, 2013;
Woodson et al., 2013). The 17D vaccine has been used in the
YF control programs in endemic areas as well as in travelers,
and the vaccine elicits long-term immunity (Gotuzzo et al.,
2013; Ishikawa et al., 2014; Patel and Simons, 2013). Rare
adverse effects including YEL-AND and YEL-AVD have been
reported (Breugelmans et al., 2013; Ishikawa et al., 2014). The
development of improved YF vaccine would be beneﬁcial
(Levine, 2011; Monath, 2005). A potentially safer Vero cell-
derived inactivated vaccine was evaluated in phase I clinical
trial (Monath et al., 2011). Candidate experimental vaccines
also include NS1 protein vaccine (Schlesinger et al., 1986), as
well as the modiﬁed vaccinia Ankara and the D4R-defective
vaccinia viruses expressing 17D prME protein (Schafer et al.,
2011). In this study, we conﬁgured recently developed iDNAs
approach (Tretyakova et al., 2014; Tretyakova et al., 2013) to
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Fig. 5. Detection of serum antibody in sera of iDNA-vaccinated or 17D virus-vaccinated BALB/c mice, by IFA. (a) BALB/c mice 1–8 were injected i.m. with 20 μg of pYF17D-16
iDNA that encoded the full-length 17D genomic RNA as a cDNA copy downstream from the CMV promoter (Fig. 1a). After iDNA injection, mice were electroporated in order to
launch live attenuated 17D vaccine in vivo and to elicit 17D-speciﬁc antibody response. (b) Mice 9–15 were vaccinated i.m. by injection with 104 PFU of 17D virus. Sera were
taken at day 21 post-vaccination and probed at 1:10 dilution with acetone-ﬁxed monolayers of Vero cell that were previously incubated with 100 PFU of 17D virus. After
incubation with mouse antisera, monolayers were incubated with FITC-conjugated goat anti-mouse IgG antibody to visualize foci of YF 17D-expressing cells. The YF 17D-
speciﬁc mouse antisera showed green ﬂuorescent cell foci indicating binding to 17D-infected Vero cells.
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prepare a novel experimental vaccine for YFV. We showed that
YF 17D iDNA plasmids launched live vaccine virus in vitro and
elicited immune response in vivo. In AG129 mice, a biologically
relevant model of YFV infection, both parental 17D and iDNA-
derived 17D viruses were found safe with a tendency to be less
hepatotropic for iDNA-derived virus.
The iDNA approach resembles the traditional “infectious clone”
technology (Bredenbeek et al., 2003; Rice et al., 1989) but does not
involve in vitro RNA transcription, thus allowing the use of iDNA
plasmid for direct vaccination in vivo. Essentially, iDNA combines
advantages of DNA and live attenuated vaccines when used in vivo
(Pushko and Lukashevich, 2014; Tretyakova et al., 2014, 2013).
Recently, we reported that two alphavirus iDNA vaccines, one based
on the TC-83 strain of Venezuelan equine encephalitis (VEEV), and
another based on the 181/25 strain of chikungunya virus (CHIKV),
initiated replication of live attenuated vaccines in vitro and elicited
protective immune responses in mice (Tretyakova et al., 2014, 2013). In
addition to extending the use of DNA immunization, iDNA technology
potentially can provide improvement to the live attenuated 17D
vaccine. Although YF 17D vaccine showed remarkable genetic stability
(Beck et al., 2014; Mantel et al., 2011), it cannot be excluded that
reversion mutations are present at a low frequency within the
manufactured vaccine. In such a case, direct vaccination with iDNA
in vivo would reduce probability of reversion mutations. Analysis of
population structure of the attenuated YF17D-204 and wild-type Asibi
virus revealed that the attenuated YFV population was homogeneous
with a restricted pattern of quasispecies variability and very limited
evidence of the existence of the Asibi consensus sequence, while Asibi
virus expressed diverse quasispecies (Beck et al., 2014). Lack of YF 17D
quasispecies was conﬁrmed by previously reported evidence of the
high ﬁdelity of YF 17D RNA polymerase (Pugachev et al., 2004).
Because iDNA represents a novel approach, more research is
needed. Although genetic stability of YF 17D virus has been demon-
strated (Beck et al., 2014; Pugachev et al., 2004), serial passages of
iDNA-derived vaccine virus in animals would be useful to directly
conﬁrm stability and safety of this vaccine in vivo. Furthermore,
additional studies including efﬁcacy can be done in other animal
models such as nonhuman primates (NHP) (Monath et al., 1981),
hamsters (Li et al., 2008) and A129 mice deﬁcient in the IFN-α/β
receptor (Meier et al., 2009). NHP remain the best model of human
disease (Monath et al., 1981; Tesh et al., 2001). The absence of
appropriate small animal model has been the major obstacle for YF
vaccine studies. Although immunocompromised animals are not
considered by FDA as appropriate challenge models for vaccine
studies, recent A129 and AG129 mouse models lacking receptors for
IFN-α/β or IFN-α/β/γ, respectively, can mimic some viscerotropic and
neurotropic characteristics of YF Asibi virus and can be used for proof-
of-concept efﬁcacy studies. These experiments are currently being
planned. In conclusion, the iDNA vaccine approach offers certain
advantages over both the traditional DNA vaccines and the live
attenuated vaccines. As any DNA vaccine, the iDNA can be formulated
to be stable at ambient temperatures (van der Heijden et al., 2013).
Potentially, the iDNA clone can serve as a reverse genetic system for
preparation of improved 17D vaccines or chimeric 17D-vectored
vaccines, such as Lassa vaccine (Bredenbeek et al., 2006) or live
dengue vaccine (Guy et al., 2011, 2010). Finally, we have shown that
the 17D iDNA vaccine induces immune response in vivo after a single
vaccination, which is a necessity for prophylactic vaccine in the
developing nations (Levine, 2011). Therefore, we conclude that the
iDNA approach may represent a feasible strategy for YF immunization.
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